Piper Sandler Maintains Neutral on Adobe, Raises Price Target to $250
Piper Sandler analyst Billy Fitzsimmons maintains Adobe (NASDAQ:ADBE) with a Neutral and raises the price target from $240 to $250.
Stocks · News reference
National Beverage Posts Downbeat Q1 Results, Joins Zumiez, Adobe And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures rose, while National Beverage and several stocks fell premarket after disappointing results, led by Zumiez down 15.7%.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Adobe shares are trading lower after the company reported Q3 financial results and issued Q4 GAAP EPS guidance below estimates.
Baird Maintains Neutral on Adobe, Raises Price Target to $250
Baird analyst Rob Oliver maintains Adobe (NASDAQ:ADBE) with a Neutral and raises the price target from $230 to $250.
mRNA Therapeutics Market Outlook Report 2026-2035 Featuring Profiles of Arcturus Therapeutics, BioNTech, CureVac, Moderna, Providence Therapeutics, RNAimmune, Recode Therapeutics, and More
The global mRNA therapeutics market (excluding COVID-19 applications) is projected to grow from USD 201 million in 2026 to USD 9.98 billion by 2035, with a 63% CAGR. Growth is driven by expanding oncology and rare disease pipelines, advances in lipid nanoparticle delivery, and strategic partnerships. However, challenges include tissue-selective delivery limitations, repeat-dose tolerability concerns, and regulatory complexities. Moderna and BioNTech dominate with approximately 70% of pipeline activity.
Arcturus Therapeutics shares are trading higher. The company announced it will present data on ARCT-810 mRNA therapy in Ornithine Transcarbamylase Deficiency at the 2026 SSIEM Annual Symposium.
8-K filing — Arcturus Therapeutics Holdings Inc. (ARCT)
Filed: 2026-08-25 AccNo: 0001193805-26-001130 Size: 589 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits